“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaClosed”
VANCOUVER, BC/ACCESSWIRE / JULY 20, 2020 / EGF THERAMED HEALTH CORP. (CSE: TMED) (OTCQB: EVAHF) (FRA: AUHP) (the “Company”) announces that it has transitority relief under Columbia’s Instrument 51-517 (Temporary Waiver of Certain Corporate Finance Requirements with Deadlines During the June 2 to August 31, 2020) on the submission of advertising acquisition reports (“BAR”) for its acquisition of a 30% stake in Pharmadelic Labs Corp. (“Pharmadelic”) on May 6, 2020 and its acquisition of a 40% stake in Green Parrot Labs Corp. (“Green Parrot”) on May 25, 2020. In accordance with the deadline set through National Instrument 51-102 (Continuous Discontinuation Obligations), the BAR for the Pharmadelic transaction expires on July 20, 2020 and the BAR for the Green Parrot transaction expires on August 10, 2020. The BAR for the Pharmadelic transaction is now expected to be submitted until September 3, 2020 and the BAR is now expected to be submitted through S 24 September 2020.
FOR MORE INFORMATION, CONTACT:
EGF THERAMED HEALTH CORP. Doug McFaul Email: [email protected] Phone: (778) 331 8five0five Web: http://www.theramedhealthcorp.com Micro- CSE: http://thecse.com/en/listings/technology/ Theramed-Health -CorporationUS OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/newsFrankfurt Borse: https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp
SOURCE: EGF Theramed Health Corp
View the accesswire.com edition: https://www.accesswire.com/598195/EGF-THERAMED-HEALTH-Provides-Update-on-Pharmadelic-Labs-and-Green-Parrot-Labs